Skip to main content

Table 4 Receiver operating characteristics analysis for each score based on the response for eculizumab treatment

From: Application of a scoring system in Japanese patients diagnosed with atypical hemolytic uremic syndrome to assess the relationship between the score and clinical responses to eculizumab

TMA/aHUS score

Partial response

Complete response

SE

SP

OR

PPV

NPV

SE

SP

OR

PPV

NPV

 ≥ 17/ < 17

0.000

1.000

–

–

0.049

0.000

1.000

–

–

0.696

 ≥ 16/ < 16

0.006

1.000

–

1.000

0.049

0.000

0.992

0.00

0.000

0.694

 ≥ 15/ < 15

0.006

1.000

–

1.000

0.049

0.000

0.992

0.00

0.000

0.694

 ≥ 14/ < 14

0.023

0.889

0.19

0.800

0.045

0.018

0.969

0.56

0.200

0.693

 ≥ 13/ < 13

0.132

0.889

1.22

0.958

0.050

0.250

0.922

3.93

0.583

0.738

 ≥ 12/ < 12

0.190

0.889

1.87

0.971

0.054

0.286

0.859

2.44

0.471

0.733

 ≥ 11/ < 11

0.408

0.778

2.41

0.973

0.064

0.625

0.703

3.95

0.479

0.811

 ≥ 10/ < 10

0.610

0.560

1.95

0.964

0.068

0.790

0.480

3.44

0.400

0.838

 ≥ 9/ < 9

0.750

0.440

2.36

0.963

0.083

0.890

0.340

4.22

0.370

0.878

 ≥ 8/ < 8

0.870

0.330

3.45

0.962

0.120

0.960

0.180

5.91

0.340

0.920

 ≥ 7/ < 7

0.910

0.330

5.30

0.964

0.167

0.980

0.130

8.42

0.331

0.944

 ≥ 6/ < 6

0.970

0.220

9.66

0.960

0.286

1.000

0.050

–

0.316

1.000

 ≥ 5/ < 5

0.990

0.220

49.43

0.961

0.667

1.000

0.020

–

0.309

1.000

 ≥ 4/ < 4

0.994

0.111

21.63

0.956

0.500

1.000

0.016

–

0.308

1.000

 ≥ 3/ < 3

1.000

0.000

–

0.951

–

1.000

0.000

–

0.304

–

  1. The estimated cutoff value with the highest odds ratio and negative predictive value is indicated in bold
  2. Abbreviations: aHUS atypical hemolytic uremic syndrome, SE sensitivity, SP specificity, NPV negative predictive value, OR odds ratio, PPV positive predictive value, TMA thrombotic microangiopathy
Back to article page

Thrombosis Journal

ISSN: 1477-9560

Contact us